This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Cystic fibrosis — pulmonary manifestationsCystic Fibrosis with Pulmonary Manifestations (CF)

ItemDetails
A. ICD-10 codeE84.0 | Special Copayment Reduction: V120
B. SynonymsCystic fibrosis (pulmonary manifestations), Mucoviscidosis, CF, pulmonary cystic fibrosis, CFTR-related disorder (pulmonary manifestations)
C. Adult onsetPossible first presentation in adulthood — in carriers of mild CFTR variants (class IV–V), the disease may not be diagnosed in childhood and may be first diagnosed in adulthood as bronchiectasis, sinusitis or male infertility
1. HistoryFirst described by Andersen in 1938; CFTR gene cloned in 1989; era of CFTR modulators since 2012
2. CausesCFTR gene mutation → chloride channel dysfunction → airway mucus hypersecretion and dehydration → chronic lung infection
3. GeneticsAutosomal recessive; CFTR gene (7q31.2); more than 2,000 variants; ΔF508 most common
4. General epidemiology1/2,500–1/3,500 white births; 1/40,000–1/100,000 in Asia; about 35,000 in the United States
5. PathophysiologyLoss of CFTR function → dehydration and increased viscosity of the airway mucus layer → impaired mucociliary clearance → bacterial colonization, chronic inflammation, bronchiectasis
6. SymptomsChronic cough, viscous sputum, recurrent lung inflammation, dyspnea, decreased lung function, sinonasal symptoms
7. SignsClubbing, cyanosis, hyperinflation, bronchiectasis, pulmonary hypertension, decreased FEV₁
8. ScreeningNewborn immunoreactive trypsinogen (IRT) screening; sweat test
9. DiagnosisSweat chloride ≥60 mmol/L + identification of 2 CFTR variants; confirmation algorithm after positive newborn screening
10. TreatmentCFTR modulators (elexacaftor/tezacaftor/ivacaftor); antibiotics; mucolytics; airway clearance; lung transplantation
11. PrognosisMedian survival about 35–40 years before the CFTR modulator era; dramatic improvement expected after modulator therapy
12. PreventionGenetic counseling, newborn screening, vaccination, infection control, early initiation of treatment
13. References10 key references

1. History

Cystic fibrosis (CF) was first described as a distinct disease in 1938 by Dorothy Hansine Andersen, who analyzed autopsy findings of children who had died of malnutrition and recurrent pneumonia at the children's hospital affiliated with Columbia University in New York. She named it "cystic fibrosis of the pancreas" at the time, which is the origin of the term "cystic fibrosis" used today. Fanconi and Bodian, who observed children with a similar clinical picture at the same time, also described this disease independently.

In 1953, Paul di Sant'Agnese discovered that the chloride concentration in the sweat of CF patients is markedly high, establishing sweat electrolyte testing as the key tool for CF diagnosis. Subsequently, in 1959, Gibson and Cooke established the standard method of the sweat test. In 1968, di Sant'Agnese comprehensively described the pattern of multisystem involvement, establishing that CF is a disease involving the whole body beyond the lungs and pancreas.

1989 was a turning point in the history of CF. The research teams of Lap-Chee Tsui, Francis Collins and John Riordan cloned the CFTR (cystic fibrosis transmembrane conductance regulator) gene located on chromosome 7 and identified the most common pathogenic variant, ΔF508 (deletion of phenylalanine at position 508). This discovery greatly advanced research on the molecular mechanisms of CF, carrier screening and genetic counseling.

In 2012, the US FDA approved ivacaftor (Kalydeco®), the first CFTR function modulator, for CF patients with the G551D variant. In 2019, the triple combination elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA, Trikafta®) was approved for a broad range of CF patients, including ΔF508 homozygotes and heterozygotes, fundamentally changing the paradigm of CF treatment.

2. Causes

The cause of CF is the presence of pathogenic variants on both alleles of the CFTR (Cystic Fibrosis Transmembrane conductance Regulator) gene. CFTR is a cAMP-dependent chloride (Cl⁻) channel located in the cell membrane, responsible for ion transport particularly in the epithelial cells of the airways, alveoli, pancreatic ducts, bile ducts, intestine, reproductive tract and sweat glands. CFTR belongs to the ABC (ATP-binding cassette) transporter family, and the channel opens and closes through ATP hydrolysis.

When CFTR function is lost, Cl⁻ secretion by epithelial cells decreases and sodium (Na⁺) reabsorption increases. In the airways, this ion transport defect causes dehydration of the airway surface liquid (ASL), thickening the mucus layer and sharply increasing its viscosity. The dehydrated mucus impairs mucociliary clearance, allowing bacteria to settle in the airways and initiating chronic infection and inflammation.

More than 2,000 CFTR variants have been identified in CF, divided into 6 classes according to their functional consequences. Class I (no protein produced/premature termination codon), class II (abnormal protein folding — most common, ΔF508), class III (gating defect), class IV (reduced conductance), class V (reduced amount of mRNA/protein), class VI (reduced cell membrane stability). Variant class is important for predicting response to CFTR modulator therapy.

ΔF508 (c.1521_1523delCTT, p.Phe508del) is the most common variant, found in about 70% of CF patients worldwide, and belongs to class II. In Korean and other Asian patients, the frequency of ΔF508 is low and other rare variants appear more often, so the ethnic variant spectrum must be considered when performing gene panel testing.

3. Genetics

CF is an autosomal recessive (AR) genetic disease. The CFTR gene is located on the long arm of chromosome 7 (7q31.2) and has 27 exons, a genomic length of about 250 kb and a 6.5 kb mRNA. The protein consists of 1,480 amino acids.

In white populations, the carrier frequency is about 1/25 (4%), consistent with a CF incidence of 1/2,500. In Asians, the carrier frequency is much lower (about 1/100–1/200). When both parents are carriers, 25% of their children develop CF and 50% become carriers. Carriers generally have no clinical symptoms.

The functional classification of CFTR variants is directly linked to the choice of treatment strategy. The triple combination elexacaftor/tezacaftor/ivacaftor can be used for variant combinations that include at least one ΔF508 (at least ΔF508 heterozygous) or variant combinations on the list of specific responsive mutations. Certain nonsense variants (class I, such as G542X and W1282X) may be candidates for read-through agents such as ataluren.

Genetic testing is essential for confirmation, determining phenotype–genotype correlation and judging the applicability of CFTR modulators. In addition to a standard panel of at least 23 variants, sequencing of all CFTR exons and analysis of large deletions/duplications are recommended.

4. General epidemiology

CF is the most common fatal autosomal recessive genetic disease in whites of Northern European descent. The birth prevalence in whites is 1/2,500–1/3,500. There are estimated to be about 35,000 CF patients in the United States and more than about 100,000 worldwide. Incidence varies greatly by race: about 1/8,000 in Hispanics, about 1/15,000–1/20,000 in African Americans and 1/40,000–1/100,000 in Asians.

CF is very rare in Korea and East Asia. Only several dozen CF patients have been reported in Korea, and a CFTR variant spectrum different from that in the West is being identified in Korean patients. Because of the low prevalence, CF in Korea can often be mistaken for other respiratory diseases, and diagnostic delays occur.

The median survival age of CF patients was reported as about 56 years in the 2022 annual report of the US Cystic Fibrosis Foundation (CF Foundation). It has improved markedly compared with before the introduction of CFTR modulators and is expected to improve further. More than about 55% of CF patients in the United States are adults.

With the introduction of newborn screening (NBS), the mean age at diagnosis has been shortened to within 6 months, and early initiation of treatment is contributing to an improved long-term prognosis.

5. Pathophysiology

The core mechanism of CF lung disease is impaired mucociliary clearance due to dehydration of the airway surface liquid (ASL) and the resulting vicious cycle of chronic bacterial infection and inflammation.

In normal airways, CFTR maintains the thickness of the Airway Surface Liquid (ASL) at about 7μm through membrane Cl⁻ secretion and through inhibition of the sodium channel (ENaC), which is functionally linked to CFTR. In this properly hydrated state, the cilia beat to move mucus, inhaled foreign matter and bacteria toward the upper airway (mucociliary clearance).

In CF, loss of CFTR function thins the ASL layer (absorptive dehydration) through decreased Cl⁻ secretion and increased Na⁺ and H₂O reabsorption due to ENaC hyperactivity, and mucus adheres to the airway surface. The dehydrated mucus becomes tens of times more viscous, cannot be moved by ciliary motion and becomes a breeding ground for bacterial colonization.

In the CF lung, Staphylococcus aureus and Haemophilus influenzae colonize initially, and Pseudomonas aeruginosa gradually becomes dominant. In the CF lung environment, Pseudomonas aeruginosa forms biofilms, acquiring antibiotic resistance and immune evasion. Transition to chronic Pseudomonas aeruginosa infection is an important turning point marking accelerated decline in lung function and a worsening prognosis.

Persistent bacterial infection induces an excessive, neutrophil-predominant inflammatory response. Elastase, proteases and reactive oxygen species released from neutrophils destroy airway tissue, and bronchiectasis progresses. Bronchiectasis is irreversible structural lung damage, manifested as a decrease in FEV₁ (forced expiratory volume in 1 second). In advanced CF, pulmonary hypertension, cor pulmonale and respiratory failure develop and become causes of death.

6. Symptoms

Respiratory symptoms: chronic, progressive cough is the earliest pulmonary symptom of CF. It is initially a dry cough but gradually changes to a productive cough with viscous or purulent sputum. Wheezing on breathing and dyspnea on exertion appear, and with progression, dyspnea at rest develops. Recurrent pulmonary exacerbations are characteristic, with fever, increased respiratory rate, decreased lung function, and increased amount and changed character of sputum. Hemoptysis may occur, and in severe cases massive hemoptysis is life-threatening. Pneumothorax is also a complication that occurs specifically in CF.

Upper airway symptoms: chronic rhinosinusitis appears in about 90% of CF patients, and nasal polyps are frequent. Recurrent headaches, nasal congestion and postnasal drip accompany it.

Systemic symptoms: wasting weight loss, fatigue and loss of appetite due to chronic infection and inflammation appear. Nutritional deficiency and declining lung function worsen each other.

After use of CFTR modulators, respiratory symptoms improve dramatically in many patients and quality of life is improving, but it should be kept in mind that already advanced bronchiectasis is irreversible.

7. Signs

Respiratory signs: on auscultation, bronchial breath sounds, crackles and wheezing are heard. On chest percussion, hyperresonance suggests lung hyperinflation. The chest wall becomes deformed into a barrel chest. Use of accessory respiratory muscles is observed.

Finger and toe signs: clubbing appears as a response to chronic hypoxia and is very characteristic of CF. Cyanosis appears when oxygenation is impaired.

Growth and nutritional signs: growth retardation and low weight are prominent in children. Muscle wasting is observed in advanced CF.

Pulmonary function test findings: spirometry typically shows an obstructive pattern. Decreased FEV₁, reduced FEV₁/FVC ratio (obstructive pattern). FEV₁ is the most important follow-up indicator of lung function in CF and is directly linked to prognosis. In adult CF, FEV₁ <30% predicted is a criterion for lung transplant evaluation.

Imaging findings: chest X-ray and HRCT show bronchiectasis (mainly upper lobes), mucus plugging, peribronchial thickening, atelectasis and air trapping. Imaging severity can be quantified with the Brasfield score or Chrispin-Norman score.

Microbiologic findings: P. aeruginosa (especially the mucoid form), S. aureus (including MRSA), Burkholderia cepacia complex, Stenotrophomonas maltophilia, nontuberculous mycobacteria (NTM) and others may be isolated from sputum or bronchoalveolar lavage (BAL) fluid.

8. Screening

Newborn Screening (NBS) for CF is standardized in most developed countries and is done by heel-prick blood sampling within 48–72 hours after birth.

Immunoreactive trypsinogen (IRT) test: IRT is measured in neonatal dried blood spots. In CF, trypsinogen accumulates in the blood because of abnormal exocrine pancreatic function, raising IRT. Because elevated IRT alone has a high false-positive rate, a two-step confirmation algorithm is applied.

IRT/DNA method: many countries use the IRT/DNA method, in which a CFTR variant panel is run directly on the same blood spot in IRT-positive newborns. If 1–2 CFTR variants are identified, the diagnosis is confirmed by sweat test.

IRT/IRT method: a method in which a second IRT measurement is made 2–4 weeks later and a sweat test is performed if both are high is also used.

Adult screening: in adults born before newborn screening was introduced, if there is bronchiectasis of unknown cause, chronic rhinosinusitis or male infertility (congenital bilateral absence of the vas deferens), sweat testing and CFTR gene testing are performed to exclude CF.

9. Diagnosis

CF is confirmed by clinical phenotype + biochemical or genetic confirmation.

Sweat test (Gibson-Cooke pilocarpine iontophoresis): the gold standard test for CF diagnosis. Sweat is induced by pilocarpine iontophoresis and the sweat chloride concentration is measured. Interpretation criteria (age 2 years or older): positive (CF diagnosis possible) ≥60 mmol/L; intermediate range 30–59 mmol/L; normal <30 mmol/L. Infants (under 6 months): positive ≥60 mmol/L. A minimum sweat amount of 75 mg (in some cases 75 mg Macroduct) is required. Intermediate-range results require further testing.

CFTR gene testing: identifies 2 pathogenic CFTR variants (on both alleles). In addition to a standard panel of at least 23 variants, sequencing of all exons and deletion/duplication analysis are recommended. Essential for confirmation after newborn screening or for intermediate-range sweat test results.

Nasal potential difference (NPD) measurement: a functional test that directly measures CFTR function in the nasal epithelium. In CF, the basal NPD becomes larger in the negative (-) direction, and the responses to amiloride and to a low-chloride Cl⁻ solution are specific. Used as an adjunct when the sweat test is inconclusive.

Intestinal current measurement (ICM): a method of measuring CFTR function in rectal biopsy tissue, widely used in Europe.

10. Treatment

CFTR modulators: targeted therapies that have driven the transformation of CF treatment. - Ivacaftor (Kalydeco®): for CFTR class III gating variants (G551D, etc.). A potentiator that increases channel open time. - Lumacaftor/ivacaftor (Lumacaftor/IVA, Orkambi®): for ΔF508 homozygotes. - Tezacaftor/ivacaftor (Tezacaftor/IVA, Symdeko®): for ΔF508 homozygotes or certain heterozygotes. - Elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA, Trikafta®/Kaftrio®): for patients aged 12 years or older with at least 1 ΔF508 (now expanded to age 2 years or older). The broadest and most potent effect. Clinical trials confirmed an absolute increase in FEV₁ of about 14%, a 63% reduction in pulmonary exacerbations and major improvements in BMI and quality of life.

Management of chronic infection: inhaled antibiotics (tobramycin inhalation solution, amikacin inhalation solution, aztreonam inhalation solution) are used in alternating cycles to reduce the P. aeruginosa burden. Oral azithromycin is given long-term 3 times a week to patients with chronic Pseudomonas aeruginosa infection for its anti-inflammatory and antibacterial effects. Acute exacerbations require IV antibiotic treatment (mainly β-lactam + aminoglycoside in combination).

Airway clearance: hypertonic saline inhalation (7% NaCl), DNase α (dornase, Pulmozyme®), positive expiratory pressure oscillation (PEP) and high-frequency chest wall oscillation (HFCWO, The Vest®) promote mucus clearance. Performing it at least twice a day is recommended.

Lung transplantation: in advanced CF with FEV₁ <30%, rapid decline in lung function, recurrent massive hemoptysis, pneumothorax and the like, bilateral lung transplantation is the treatment of last resort. 5-year survival after transplantation is about 50–60%.

Nutritional management: a high-calorie, high-fat diet, pancreatic enzyme replacement (PERT) and fat-soluble vitamin (A, D, E, K) supplementation are essential.

11. Prognosis

The prognosis of CF has improved markedly over the past several decades. In the 1970s, the mean survival age of CF patients was under 10 years, but in the 2022 annual report of the US CF Foundation the median predicted survival age exceeded 56 years. This is the result of the introduction of newborn screening, optimized antibiotic treatment, nutritional management, advances in airway clearance and, above all, the introduction of CFTR modulators.

As the ELX/TEZ/IVA triple combination has been applied to eligible patients, decreasing trends in hospitalization rates for pulmonary exacerbations and in the number of lung transplants have been reported. However, in patients whose bronchiectasis has already progressed, modulators cannot reverse structural lung damage, so early diagnosis and early initiation of treatment are key in determining the long-term prognosis.

For the minority of patients with variants on which CFTR modulators have no effect (some class I variants, etc.) and for carriers of rare variants seen in Korean and other Asian patients, targeted treatment approaches may be limited. In this group, conventional treatment is optimized and participation in clinical trials is considered.

12. Prevention

Expanding newborn screening: newborn screening (NBS) is the most effective preventive strategy for preserving lung function through early diagnosis and initiation of treatment. Introduction and expansion of CF NBS in Korea is needed.

Genetic counseling and carrier testing: carrier testing is recommended for siblings and partners of patients with CF. For couples who are both carriers, preconception genetic counseling makes them aware of the 25% risk in each pregnancy. Prenatal diagnosis (chorionic villus sampling or amniocentesis) or preimplantation genetic diagnosis (PGD) is possible.

Infection prevention: to prevent cross-infection between CF patients, isolation principles are strictly observed (no contact between CF patients, especially those infected with B. cepacia complex). Vaccinations against influenza, pneumococcus, COVID-19 and others are kept up to date.

Preventive nutritional management: regular nutritional assessment and pancreatic enzyme replacement prevent nutritional deficiency and minimize growth retardation.

Environmental management: avoiding smoke exposure, minimizing indoor air pollutants and appropriate humidification help maintain airway health.

13. References

  1. Elborn JS. Cystic fibrosis. Lancet. 2016;388(10059):2519–2531. PMID:27140670
  2. Riordan JR, Rommens JM, Kerem B, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science. 1989;245(4922):1066–1073. PMID:2475911
  3. Middleton PG, Mall MA, Dřevínek P, et al. Elexacaftor–tezacaftor–ivacaftor for cystic fibrosis with a single Phe508del allele. N Engl J Med. 2019;381(19):1809–1819. PMID:31697902
  4. Flume PA, O'Sullivan BP, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med. 2007;176(10):957–969. PMID:17761616
  5. Castellani C, Duff AJA, Bell SC, et al. ECFS best practice guidelines: the 2018 revision. J Cyst Fibros. 2018;17(2):153–178. PMID:29506920
  6. Cystic Fibrosis Foundation. Cystic Fibrosis Foundation Patient Registry 2022 Annual Data Report. Bethesda, Maryland; 2023.
  7. Savant AP, McColley-Strickland M, Millar SJ, et al. Cystic fibrosis year in review 2024. Pediatr Pulmonol. 2025. PMC:12333320
  8. Sosnay PR, Siklosi KR, Van Goor F, et al. Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene. Nat Genet. 2013;45(10):1160–1167. PMID:23974870
  9. Ratjen F, Bell SC, Rowe SM, Goss CH, Quittner AL, Bush A. Cystic fibrosis. Nat Rev Dis Primers. 2015;1:15010. PMID:27189798
  10. Andersen DH. Cystic fibrosis of the pancreas and its relation to celiac disease: a clinical and pathological study. Am J Dis Child. 1938;56(2):344–399. doi:10.1001/archpedi.1938.01980140114013